Can MRI data improve decision-making about the need for a biopsy?

Last week we noted that adding MRI data to the Partin tables and to the Kattan/MSKCC nomograms did not seem to improve the accuracy of prognosis of outcomes after radical prostatectomy. … READ MORE …

Risk for suicide among prostate cancer patients

An article just published in the journal Cancer states that — at least here in the USA — there was no significant increase in risk for suicide within the first year after diagnosis among men diagnosed with prostate cancer between 2000 and 2014 … READ MORE …

Maybe coming soon to a medical center near you?

Our regular readers will remember that we have commented on and off on the development of different types of system that (maybe) can be used to test for risk of cancer based on smell … an ability that has been clearly demonstrated among certain trained dogs and one of two electronic systems. … READ MORE …

Can MRI data improve older, pre-treatment, prognostic methods?

An obvious but previously unanswered question has been whether adding data from the results of MRI scans to the data used in the Partin tables and in the pre-surgical Kattan nomogram (also known as the Memorial-Sloan Kettering Cancer Center or MSKCC nomogram) can improve the accuracy of these two commonly used prognostic methods. … READ MORE …

How urologists are thinking about focal therapy for localized prostate cancer

A newly published study in Urologic Oncology has reported data from a survey carried out by researchers at the National Cancer Institute into “the current practice patterns and views among urologists regarding focal therapy for prostate cancer”. … READ MORE …

Is Gleason 6 prostate cancer really “more lethal” in black men?

A commentary in Renal and Urology News this morning is entitled “Gleason 6 prostate cancer is more lethal in black men”. … READ MORE …

Topsalycin in the treatment of prostate cancer: an update

Some 3 years ago we first commented on a Phase II trial of a drug now called topsalycin (but then known as PRX302) in the treatment of low- to intermediate-risk, localized prostate cancer. … READ MORE …